Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The hydroxypyridone ciclopirox olamine belongs to the antimycotic drugs used for the treatment of superficial mycoses. In contrast to the azoles and other antimycotic drugs, its specific mode of action is only poorly understood. To investigate the mode of action of ciclopirox olamine on fungal viability, pathogenicity, and drug resistance, we examined the expression patterns of 47 Candida albicans genes in cells grown in the presence of a subinhibitory concentration (0.6 μg/ml) of ciclopirox olamine by reverse transcription-PCR. In addition, we used suppression-subtractive hybridization to further identify genes that are up-regulated in the presence of ciclopirox olamine. The expression of essential genes such as ACT1 was not significantly modified in cells exposed to ciclopirox olamine. Most putative and known virulence genes such as genes encoding secreted proteinases or lipases had no or only moderately reduced expression levels. In contrast, exposure of cells to ciclopirox olamine led to a distinct up- or down-regulation of genes encoding iron permeases or transporters (FTR1,FTR2,FTH1), a copper permease (CCC2), an iron reductase (CFL1), and a siderophore transporter (SIT1); these effects resembled those found under iron-limited conditions. Addition of FeCl 3 to ciclopirox olamine-treated cells reversed the effect of the drug. Addition of the iron chelator bipyridine to the growth medium induced similar patterns of expression of distinct iron-regulated genes (FTR1,FTR2). While serum-induced yeast-to-hyphal phase transition of C. albicans was not affected in ciclopirox olamine-treated cells in the presence of subinhibitory conditions, a dramatic increase in sensitivity to oxidative stress was noted, which may indicate the reduced activities of iron-containing gene products responsible for detoxification. Although the Candida drug resistance genes CDR1 and CDR2 were up-regulated, no change in resistance or increased tolerance could be observed even after an incubation period of 6 months. This was in contrast to control experiments with fluconazole, in which the MICs for cells incubated with this drug had noticeably increased after 2 months. These data support the view that the antifungal activity of ciclopirox olamine may at least be partially caused by iron limitation. Furthermore, neither the expression of certain multiple-drug resistance genes nor other resistance mechanisms caused C. albicans resistance to this drug even after long-term exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 2×
“albicans the up-regulation of MDR1, CDR1, and CDR2 are implicated in the development of fluconazole resistance, while for CDR3 and CDR4, no correlation between mRNA levels and the degree of resistance was reported (12, 42, 53).”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
A High-Affinity Iron Permease Essential for Candida albicans Virulence
Ramanan, N., & Wang, Y. (2000) · Science · doi:10.1126/science.288.5468.1062 · Cited by 336 · cited 8×
“This inverse regulation of these permease-encoding genes has been shown to reflect iron-limiting conditions (47), suggesting that cells treated with ciclopirox olamine grow in an environment with insufficient iron concentrations.”
BackgroundResultInfluentialIdentification and Characterization of TUP1-Regulated Genes in Candida albicans
Braun, B. R., Head, W. S., Wang, M. X., & Johnson, A. D. (2000) · Genetics · doi:10.1093/genetics/156.1.31 · Cited by 306
Hube, B., Stehr, F., Bossenz, M., Mazur, A., Kretschmar, M., & Schäfer, W. (2000) · Archives of Microbiology · doi:10.1007/s002030000218 · Cited by 212 · cited 4×
“Gene Gene function (reference) Expression levela CIC FLC SAP1 Secreted protease (30) , 0.89 (0.095) 1, 2.28 (0.81) SAP2 Secreted protease (30) (2), 0.76 (0.11) , 0.79 (0.145) SAP3 Secreted protease (30) , 0.95 (0.275) , 1.1 (0.105) SAP4 Secreted protease (30) 2, 0.50 (0.195) 0 SAP5 Secreted protease (30) 2, 0.5 (0.09)…”
BackgroundInfluentialSelf-citationDe Backer, M. D., Ilyina, T., Ma, X.-J., Vandoninck, S., Luyten, W. H. M. L., & Vanden Bossche, H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1660-1670.2001 · Cited by 211 · cited 1×
“One way of elucidating the mode of action of a particular drug is to examine the gene expression profiles of cells treated with the drug (3, 13).”
Background
Research works printed but not linked: 45
- Abrams, B. B., H. Hänel, and T. Hoehler. 1992. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin. Dermatol.9:471-477.
- 10.1128/jb.179.23.7210-7218.1997 · DOI · Paper page
- 10.1128/AAC.44.5.1255-1265.2000 · DOI · Paper page
- 10.1099/00221287-144-1-55 · DOI · Paper page
- 10.1128/AAC.38.4.648 · DOI · Paper page
- Braga, P. C., S. Maci, M. DalSasso, and M. Bohn. 1996. Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy (Basel)42:259-265. · doi:10.1159/000239453
- Braga, P. C., G. Piatti, E. Conti, and F. Vignali. 1992. Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. Drug Res.42:1368-1371.
- 10.1126/science.277.5322.105 · DOI · Paper page
- 10.1093/genetics/155.1.57 · DOI · Paper page
- 10.1099/00221287-146-11-2743 · DOI · Paper page
- Diasio, R. B., J. E. Bennett, and C. E. Myers. 1978. Mode of action of 5-fluorocytosine. Biochem. Pharmacol.27:703. · DOI
- 10.1073/pnas.93.12.6025 · DOI · Paper page
- Dittmar, W., W. Grau, W. Raether, E. Schrinner, and W. H. Wagner. 1981. Microbiological laboratory studies with ciclopiroxolamine. Drug Res.31:1317-1322.
- Dittmar, W., and G. Lohaus. 1973. HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Drug Res.23:670-674.
- 10.1099/00221287-145-9-2415 · DOI · Paper page
- 10.1128/IAI.70.7.3689-3700.2002 · DOI · Paper page
- 10.1007/BF00259685 · DOI · Paper page
- 10.1016/S0378-1119(98)00412-0 · DOI
- 10.1099/00221287-143-2-331 · DOI · Paper page
- Gasparini, G., D. Contini, A. Torti, C. Guidarelli, A. Lasagni, and R. Caputo. 1986. The effect of ciclopiroxolamine investigated by means of the freeze-fracture technique. Mykosen29:539-544. · doi:10.1111/j.1439-0507.1986.tb03956.x
- Gupta, A. K. 2001. Ciclopirox: an overview. Int. J. Dermatol.40:305-310. · DOI
- 10.1016/S0190-9622(94)70112-1 · DOI
- 10.1111/j.1574-6968.1998.tb13223.x · doi:10.1111/j.1574-6968.1998.tb13223.x · Paper page
- 10.1099/00221287-147-4-879 · DOI · Paper page
- 10.1099/00221287-147-8-1997 · DOI · Paper page
- 10.1111/j.1365-2958.1994.tb01269.x · DOI · Paper page
- 10.1128/IAI.69.6.3939-3946.2001 · DOI
- Iwata, K., and H. Yamaguchi. 1981. Studies on the mechanism of antifungal action of ciclopiroxolamine. Drug Res.31:1323-1327.
- 10.1128/jb.179.7.2331-2338.1997 · DOI · Paper page
- Korting, H. C., and M. Grundmann-Kollmann. 1997. The hydroxypyridones: a class of antimycotics of its own. Mycoses40:243-247. · DOI · Paper page
- Kruse, R., W. Hengstenberg, H. Hänel, and W. Raether. 1991. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox. Pharmacology43:247-255. · doi:10.1159/000138852
- 10.1016/S0378-1119(97)00069-3 · DOI
- Lohaus, G., and W. Dittmar. 1981. The chemistry of antimicrobially active 1-hydroxy-2-pyridones. Drug Res.31:1311-1316.
- Losberger, C., and J. F. Ernst. 1989. Sequence of the Candida albicans gene encoding actin. Nucleic Acids Res.17:9488. · DOI · Paper page
- 10.1093/jac/47.5.527 · DOI · Paper page
- Maneu, V., A. M. Cervera, J. P. Martinez, and D. Gozalbo. 1996. Molecular cloning and characterization of a Candida albicans gene (EFB1) coding for the elongation factor EF-1β. FEMS Microbiol. Lett.145:157-162.
- Mercer, E. I. 1991. Morpholine antifungals and their mode of action. Biochem. Soc. London Trans.19:788-793. · doi:10.1042/bst0190788
- Reitze, H. K., D. R. Dannhorn, H. Hänel, and K. A. Seitz. 1993. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox. Mycoses36:385-395. · doi:10.1111/j.1439-0507.1993.tb00727.x
- Sakurai, K., T. Sakaguchi, H. Yamaguchi, and K. Iwata. 1978. Mode of action of 6-cyclohexyl-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296). Chemotherapy (Tokyo)24:68-76. · DOI
- Sakurai, K., T. Sakaguchi, H. Yamaguchi, and K. Iwata. 1978. Studies on uptake of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296) by Candida albicans. Chemotherapy (Tokyo)24:146-153. · doi:10.1159/000237774
- Sambrook J. and D. W. Russell. 2001. Molecular cloning: a laboratory manual 3rd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor N.Y.
- 10.1016/0378-1119(93)90668-S · DOI
- Sugiyama, Y., S. Nakashima, F. Mirbod, H. Kanoh, Y. Kitajima, M. A. Ghannoum, and Y. Nozawa. 1999. Molecular cloning of a second phospholipase B gene, CaPLB2 from Candida albicans. Med. Mycol.37:61-67.
- 10.1074/jbc.274.53.38061 · DOI · Paper page
- 10.1128/IAI.66.5.1953-1961.1998 · DOI · Paper page
Cited by
Candida albicans Cell Wall Proteins
Chaffin, W. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-07 · Cited by 515
“There was no effect of treatment with ciclopirox olamine or fluconazole (RT-PCR [272]), caspofungin (RT-PCR, transcriptional profiling [210, 272]), or amphotericin B, ketoconazole, and flucytosine (transcriptional profiling [210]).”
BackgroundAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
Almeida, R. S., Brunke, S., Albrecht, A., Thewes, S., Laue, M., Edwards, J. E., Filler, S. G., & Hube, B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000217 · Cited by 330
“albicans [81] and the anti Candida activity of ciclopiroxolamine, a potent antifungal agent, is proposed to be mediated by iron chelation [82–84].”
BackgroundSelf-citationCandida albicans iron acquisition within the host
Almeida, R. S., Wilson, D., & Hube, B. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00570.x · Cited by 199
“Finally, the anti-Candida activity of ciclopirox olamine, a potent antifungal agent, is proposed to be caused by iron chelation (Niewerth et al., 2003; Lee et al., 2005; Sigle et al., 2005).”
BackgroundSelf-citationGuideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k)
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., et al. (2021) · Mycoses · doi:10.1111/myc.13248 · Cited by 184
Self-citationDrug repurposing as an alternative for the treatment of recalcitrant bacterial infections
Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., GarcÃa-Contreras, S. J., & GarcÃa-Contreras, R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00282 · Cited by 168
“The antifungal mechanism of ciclopirox remains unknown, though it is known to not inhibit ergosterol biosynthesis (Niewerth et al., 2003), and likely interferes with iron metabolism (Sigle et al., 2005).”
BackgroundCovalently linked cell wall proteins of Candida albicans and their role in fitness and virulence
Klis, F. M., Sosinska, G. J., de Groot, P. W. J., & Brul, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00541.x · Cited by 165
Enjalbert, B., & Whiteway, M. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.7.1203-1210.2005 · Cited by 145
“Drug response genes are quickly and significantly induced by the continued presence of farnesol in the fresh medium, a response similar to that generated by antimycotic drugs (25, 27, 30).”
BackgroundIron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis)
Mendling, W. (2015) · Mycoses · doi:10.1111/myc.12292 · Cited by 117
Jin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
“76 ciclopirox olamine has minimal ability to induce drug resistance [18].”
BackgroundCarlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069646 · Cited by 73
“albicans revealed gene expression level changes similar to those exhibited in iron-deprived conditions [17,18].”
BackgroundInfluentialFungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans
Brena, S., Cabezas-Olcoz, J., Moragues, M. D., Fernández de Larrinoa, I., Domínguez, A., Quindós, G., & Pontón, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00892-10 · Cited by 69
Chew, S. Y., & Than, L. T. L. (2016) · Mycoses · doi:10.1111/myc.12455 · Cited by 63
Cheng, S., Clancy, C. J., Nguyen, K. T., Clapp, W., & Nguyen, M. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00182-07 · Cited by 62
Duan, X., Xie, Z., Ma, L., Jin, X., Zhang, M., Xu, Y., Liu, Y., Lou, H., & Chang, W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01951-21 · Cited by 31
“potently inhibits fungal cell growth (12).”
Metadata
- Authors
- Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Korting, H. C., & Hube, B.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-06
- Volume
- 47
- Issue
- 6
- Pages
- 1805-1817
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2095902301
- Cited by
- 144
- References
- 14
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.